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Background: Emerging evidence suggests beneficial effects of omega-3 fatty acids on diabetic complications. The
present study compared the progressive effects of metformin and flax/fish oil on lipid metabolism, inflammatory
markers, and liver and renal function test markers in streptozotocin-nicotinamide-induced diabetic rats.
Methods: Streptozotocin-induced diabetic rats were randomized into control and four diabetic groups:
streptozotocin (STZ), metformin (200 mg/kg body weight (b.w)/day (D)), flax and fish oil (500 mg/kg b.w/D).
Results: Metformin and flax and fish oil exhibited increased expression of transcription factor peroxisome
proliferator-activated receptor γ while the treatment downregulated sterol regulatory element-binding protein 1
and nuclear factor kβ as compared to those of the STZ group. Apart from modulation of transcription factor
expression, the expression of fatty acid synthase, long chain acyl CoA synthase, and malonyl-CoA-acyl carrier protein
transacylase was lowered by flax/fish oil treatment. Serum cholesterol, triglycerides, and VLDL were also significantly
reduced in the treatment groups as compared to those in the STZ group. Although pathological abnormalities were
seen in the liver and kidneys of rats on metformin, no significant changes in liver/renal function markers were observed
at day 15 and day 30 of the treatment groups. Flax/fish oil had protective effects toward pathological abnormalities in the
liver and kidney. Flax/fish oil improved lipid profile and alkaline phosphatase at day 30 as compared to that at day 15.
Conclusions: The present study demonstrates potential beneficial effects of metformin and flax/fish oil intervention in
improving serum lipid profile by regulating the expression of transcription factors and genes involved in lipid metabolism
in diabetic rats. In addition, these interventions also lowered the expression of atherogenic cytokines. The protective
effects of flax/fish oil are worth investigating in human subjects on metformin monotherapy.
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Omega-3 polyunsaturated fatty acids (n-3 PUFA) consti-
tute a fundamental part of cell membranes and exhibit a
diverse range of membrane functions including func-
tioning of transporters, signal transduction pathways,
and gene expression (Liu and Ma 2014; Ander et al.
2003). Alpha-linolenic acid (ALA; 18:3 n-3) is a short* Correspondence: kuaniket@gmail.com
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food item) (Dessì et al. 2013; Mozaffarian and Wu 2012;
Connor 2000) while eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA; 22:6 n-3) are the long
chain n-3 PUFA derived from a seafood source, fish oil
(Swanson et al. 2012). There is strong scientific evidence
demonstrating anti-inflammatory, anti-atherogenic, vaso-
dilatory, and lipid-lowering properties of n-3 PUFA
(Jangale et al. 2013; Mozaffarian and Wu 2012; Connor
2000) due to which they have been implicated in some
chronic diseases like cardiovascular disease (Ander et al.
2003), diabetes (Wu et al. 2012), and autoimmune diseasese is distributed under the terms of the Creative Commons Attribution 4.0
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sidered as significant nutrients involved in metabolic regu-
lation. There is a recent surge in research on effects of
functional foods, like n-3 PUFA for the management of
type 2 diabetes mellitus (T2DM).
Diabetes consists of a group of metabolic disorders in-
volving distinct pathogenic mechanisms with hypergly-
cemia, arising due to impaired metabolism of glucose,
lipids, and proteins (Prabhakar et al. 2013). T2DM is fre-
quently associated with abnormal lipid profile (Ozder
2014) with perturbations in the lipid metabolism affected
by abnormalities in the expression of hepatic transcrip-
tion factors and genes (Erejuwa et al. 2012). Moreover,
diabetics are more prone to develop chronic complica-
tions related to cardiovascular, renal (Forbes and Cooper
2013), and peripheral vascular tissues (King 2008).
Several oral hypoglycemic drugs such as biguanides,
sulfonylurea, and thiazolidenediones are commonly used
for the treatment of T2DM. Metformin is an old and widely
used first-line agent, known for its anti-hyperglycemic
properties, and is also reported to improve lipid profile, fat
redistribution (Rojas and Gomes 2013), and chronic liver
diseases (Zheng et al. 2015) and lower microvascular
and macrovascular complications associated with T2DM
(Kooy et al. 2009). Though it has rarely been reported to
induce hepatocellular and cholestatic hepatic injury (Saadi
et al. 2013) and hepatotoxicity (Miralles-Linares et al.
2012), there are very few reports examining its long-term
effects for the management of T2DM.
Some investigations have evaluated the individual ef-
fects of metformin (Wang et al. 2014) or n-3 PUFA on
the regulation of lipid metabolism genes in diabetes
(Devarshi et al. 2013). The lipid-lowering actions of n-3
PUFA are attributed to the regulation of key transcrip-
tion factors like peroxisome proliferator-activated re-
ceptors (PPAR) and sterol regulatory element-binding
protein (SREBP), that control hepatic lipid metabolism
(Di Minno et al. 2012). However, there are some con-
flicting results stating that supplementation with fish oil
does not delay the onset of diabetes in rats at 12 months
of age (Cummings et al. 2010) while other reports state
that n-3 PUFA slows the progression of T2DM and its
complications (Nettleton and Katz 2005). However, there
is lack of evidence for these effects of n-3 PUFA in
T2DM and the underlying molecular mechanisms have
not been well evaluated (Devarshi et al. 2013; Wu et al.
2012). A review by Hendrich points a need to carry out
high-quality studies to assess the effects of ALA (Hendrich
2010). The above reports suggest the need for a meticu-
lous evaluation of effects of ALA, EPA, and DHA on lipid
metabolism and its underlying mechanism.
It is well known that streptozotocin (STZ) has a select-
ive cytotoxic action on β-cells in the islets of Langerhans
whereas nicotinamide has a partial protective role on β-cells against STZ (Szkudelski 2012) and is commonly
used for induction of type 2 diabetes mellitus in experi-
mental animals (Devarshi et al. 2013; Pari and Saravanan
2007; Saravanan and Pari 2007; Brenna et al. 2003). Add-
itionally, STZ-nicotinamide is considered as a suitable
T2DM model to study the effects of metformin as well
as herbal (Maheshwari et al. 2014; Sharma et al. 2012;
Mohammadi et al. 2012; Li et al. 2011) and nutritional
(Devarshi et al. 2013; Jangale et al. 2013) interventions
as indicated by several animal studies. We selected per-
ipheral blood mononuclear cells (PBMCs) to study gene
expression profile since the blood is the most accessible
tissue in humans, and as the profile of multiple tissues is
shared with PBMCs, they reflect important metabolic
changes in the liver (Konieczna et al. 2014). However,
there are no reports examining the temporal effects of
metformin and flax/fish oil diets on the lipid metabolism
and biochemical markers in T2DM. Moreover, potential
of these treatments to affect duration of the disease is
poorly understood.
We hypothesized that metformin and omega-3 fatty
acids could improve lipid metabolism and inflammatory
cytokines by modulating the expression of transcription
factors in STZ-nicotinamide-induced diabetic rats. The
objectives of the present study were to examine the
comparative effects of metformin and omega-3 fatty
acids on serum lipid profile, expression of transcription
factors and genes involved in lipid metabolism, and in-
flammation in STZ-nicotinamide-induced diabetic
rats. Additionally, the progressive effects of these treat-
ments on liver/renal function test markers and histo-
logical changes in these tissues were evaluated. We
also compared the effects of these treatments on the
above parameters at post treatment day 15 (D15) and




Flax oil (Alvel-500) capsules were purchased from Real
World Nutritional Laboratory (Pune, India) that con-
tained 50 % alpha-linolenic acid (ALA), 20 % oleic acid,
and 12 % linoleic acid. Fish oil capsules (Maxepa) were
purchased from Merck Limited (Goa, India) which con-
tained 60 % EPA and 40 % DHA. Streptozotocin (STZ),
nicotinamide (Sigma Life Sciences, USA), and metformin
(Glycomet 250 mg; USV Limited) were purchased from
a local pharmacy.
Experimental animals
The study was carried out as per the CPCSEA (Committee
for the Purpose of Control and Supervision of Experiments
on Animals) guidelines after the approval of Institutional
Animal Ethics Committee (Ref. No: BVDUMC/189/2014-
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and 200 g were procured from the institutional animal
house and maintained under standard conditions through-
out the experimentation (temperature 25 ± 2 °C, 12-h
light:12-h dark cycle). Animals were fed with standard pel-
let diet (Nutrivet life science, Pune, M.S., India), and water
was supplied ad libitum.
Diabetes induction
Animals were randomly assigned to five groups (n = 6).
Diabetes was induced by administration of nicotinamide
(110 mg/kg body weight) in saline through intra-
peritoneal (i.p) injection. After 15 min, STZ was adminis-
tered (65 mg/kg body weight i.p) in sodium citrate buffer,
pH 4.0. The fasting blood glucose levels of the rats were
estimated after 48 h and on day 7 of STZ injection. Stable
hyperglycemia was confirmed by elevated fasting blood
glucose levels on day 7 after STZ injection. Animals with
fasting blood glucose levels above 200 mg/dl were consid-
ered as diabetic and used for the study. After development
of stable hyperglycemia, metformin or flax/fish oil treat-
ment was given for 30 days. The dose of flax and fish oil
was based on the earlier study carried out in our labora-
tory (Chavan et al. 2013). The study protocol is given in
Fig. 1. Animals were randomly assigned to one of the fol-
lowing groups: group I: control group (n = 6): received
feed and water normally throughout the experiment;
group II: STZ-induced diabetic group (n = 6): adminis-
tered nicotinamide (110 mg/kg body weight) and STZ
(65 mg/kg body weight) i.p single dose; group III: metfor-
min group (n = 6): administered metformin (200 mg/kg,Fig. 1 Study designbody weight/D p.o); group IV: flax oil group (n = 6): ad-
ministered flax oil (500 mg/kg body weight/D, p.o); group
V: fish oil group (n = 6): administered fish oil (500 mg/kg
body weight/D, p.o). After 15 days of treatment, animals
were fasted overnight and blood was collected by retro-
orbital puncture. Animals were sacrificed after 30 days of
treatment. Liver and kidney tissues were excised immedi-
ately, washed in saline, weighed, and stored in 10 % neu-
tral buffered formalin for histological analysis. Blood was
collected and centrifuged at 2000 rpm for 15 min to col-
lect serum for biochemical estimations.
Blood biochemistry
Serum glucose, total cholesterol, triglyceride, high-density
lipoprotein (HDL), low-density lipoprotein (LDL), serum
glutamic oxaloacetic transaminase (SGOT), serum glu-
tamic pyruvic transaminase (SGPT) and alkaline phos-
phatase (ALP), total bilirubin, creatinine, urea, albumin,
and total protein were estimated using commercial kits
(Coral Clinical Systems, Goa, India). Very low-density
lipoprotein cholesterol (VLDL) was estimated by using the
formula: (triglyceride/5).
Quantitative real-time reverse transcription-polymerase
chain reaction analysis
PBMCs were isolated by density gradient centrifugation
by layering the blood sample over Histopaque-1077
(Sigma-Aldrich, Inc., USA). RNA was isolated by TRIzol
(Invitrogen Co., Carlsbad, CA, USA) method. Total
RNA was quantified using NanoDrop (ND1000, USA).
The quality of RNA was analyzed by agarose gel
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pared by using high-capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems). Standard quantitative real-
time transcription-polymerase chain reaction (qRT-PCR)
was performed with the use of SYBR Green master mix
(Applied Biosystems) for the following genes: PPARγ,
SREBP1, nuclear factor kappa β (NFκβ), fatty acid syn-
thase (FAS), long chain acyl CoA synthetases (ACSL),
malonyl-CoA-acyl carrier protein transacylase (MCAT),
tumor necrosis factor α (TNFα). KicqStart Primers (Sigma,
USA) were used for gene expression studies and are
listed in Table 1. qRT-PCR was performed using the
Applied Biosystems 7300 Standard system. The reac-
tions for each gene were performed in duplicate. Rela-
tive expression levels of genes were calculated and
expressed as 2ΔCT where ΔCT is CT (GAPDH)–CT (tar-
get gene) and this method is a modification of 2−ΔΔCT
method (Gaines et al. 2010).Histological analysis
Paraffin-embedded liver and kidney tissues were cut at
4 μm and stained with hematoxylin and eosin. The slides
were examined under a binocular microscope (Make:
Olympus IX71) and photographed by using Image Pro
Plus (v5.1.2.59).Table 1 List of primers used for quantitative real-time PCR
Gene Primer name Sequence (5′−3′)
GAPDH GAPDH F AGTTCAACGGCACAGTCAAG
GAPDH R TACTCAGCACCAGCATCACC
PPARγ PPARγ F AAGACAACAGACAAATCACC
PPARγ R CAGGGATATTTTTGGCATACTC
SREBP1 SREBP F AAACCTGAAGTGGTAGAAAC
SREBP R TTATCCTCAAAGGCTGGG
NFKB NFKB F AAAAACGAGCCTAGAGATTG
NFKB R ACATCCTCTTCCTTGTCTTC
FAS FAS F AAAAGGAAAGTAGAGTGTGC
FAS R GACACATTCTGTTCACTACAG
ACSL ACSL F ACATTATGAACGATTGCTCC
ACSL R GCATTACACACTCTACAACG
MCAT MCAT F AAAACTCTAGGCTCAATCAAC
MCAT R GGATGTGTGTATTTATGCCC
TNFα TNFα F CTCACACTCAGATCATCTTC
TNFα R GAGAACCTGGGAGTAGATAAG
GAPDH glyceraldehyde-3-phosphate dehydrogenase, PPARγ peroxisome
proliferator-activated receptors γ, SREBP1 sterol regulatory element-binding
protein 1, NFκβ nuclear factor kappa β, FAS fatty acid synthase, ACSL long chain
acyl CoA synthetases, MCAT malonyl-CoA-acyl carrier protein transacylase,
TNFα tumor necrosis factor α (Make: Sigma-Aldrich; F forward primer sequence,
R reverse primer sequence)Statistical analysis
Results are presented as mean ± standard error (SE). All
the statistical analyses were performed using SPSS PC+
package (Version 20, Chicago, IL, USA). The data were
checked for normal distribution by testing for skewness.
Skewed variables were transformed to normality using
log to the base 10 transformation. Statistical differences
between means in different groups were determined
using one-way analysis of variance (ANOVA) test followed
by post hoc Bonferonni multiple correction test. Mean
values of various parameters from each group at D15 were
compared with those at D30 using Student’s t test. P ≤
0.05 was considered statistically significant.
Results
Food intake, body weights, and organ weights
The food intake of animals from the STZ group was
higher at D1 (p < 0.01), D15, and D30 (p < 0.05) as com-
pared to that from the control. The body weights were
lower at D15 (p < 0.05) and D30 (p < 0.01) when com-
pared with those of the control (Table 2). Liver weights,
hepatic index, and kidney weights were comparable
while kidney index (p < 0.01) was higher in the STZ
group as compared to that in the control (Table 2).
Serum glucose levels
Serum glucose levels were significantly higher (p < 0.01)
in the STZ group than those in the control at D15 and
D30 (Table 3).
Comparison of glucose levels at D15 and D30 within the
groups
Glucose levels in the control, STZ, metformin, and flax
oil groups were comparable at D15 and D30. However,
glucose levels in the fish oil group were lower (p < 0.05)
at D30 as compared to those at D15 (Table 5).
Lipid profile
At D15, the STZ group had higher serum cholesterol
(p < 0.01), HDL, and LDL levels (p < 0.01) than the
control group. A higher trend was observed for trigly-
ceride and VLDL (p = 0.068) levels in the STZ group
than for those in the control group. Animals from the
metformin-treated group had lower cholesterol (p < 0.05),
HDL, and LDL (p < 0.01) than those in the STZ group.
The fish oil treatment group also lowered HDL and LDL
levels (P < 0.05) than the STZ group (Table 3).
At D30, higher serum cholesterol (p < 0.05), triglycer-
ide, and VLDL levels (p < 0.01) were seen in the STZ
group than in the control. Metformin group lowered
cholesterol, triglyceride, and VLDL (p < 0.01) as com-
pared to the STZ group. Flax oil treatment group low-
ered triglycerides and VLDL levels (p < 0.01) than the
STZ group. Fish oil treatment group lowered cholesterol,
Table 2 Food intake and body, liver, and kidney weights of animals
Control (n = 6) STZ (n = 6) Metformin (n = 6) Flax oil (n = 6) Fish oil (n = 6)
Food intake (g)
Day 1 14.66 ± 3.58 30.83 ± 0.21** 33.66 ± 0.58 31.83 ± 2.69 30.00 ± 0.65
Day 15 12.66 ± 2.41 23.33 ± 2.07* 27.00 ± 1.27 28.33 ± 1.80 16.66 ± 2.59
Day 30 16.00 ± 2.22 26.50 ± 3.55* 27.00 ± 1.89 33.66 ± 0.45 31.50 ± 1.93
Body weights (g)
Day 1 236.50 ± 3.48 235.50 ± 8.54 235.50 ± 13.91 245.83 ± 3.84 243.16 ± 15.15
Day 15 292.16 ± 6.55 232.33 ± 20.28* 201.33 ± 14.02 231.83 ± 12.68 202.50 ± 11.64
Day 30 345.50 ± 10.47 223.33 ± 30.34** 176.50 ± 14.93 211.33 ± 13.90 198.33 ± 11.47
Liver and kidney weights
Liver weight (g) 9.97 ± 0.60 7.68 ± 0.59 6.60 ± 0.50 7.60 ± 0.51 8.24 ± 0.59
Liver index (%) 2.87 ± 0.12 3.60 ± 0.31 3.78 ± 0.19 3.62 ± 0.20 4.17 ± 0.24
Kidney weight (g) 1.60 ± 0.13 1.89 ± 0.08 1.76 ± 0.12 1.91 ± 0.07 1.84 ± 0.03
Kidney index (%) 0.46 ± 0.03 0.90 ± 0.08** 1.01 ± 0.06 0.91 ± 0.04 0.94 ± 0.05
Data are presented as mean ± SE
*p < 0.05, **p < 0.01 for comparison between the control and STZ group
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STZ group (Table 3).
Comparison of lipid profile parameters at D15 and D30
within the groups
In the STZ group, serum HDL and LDL levels were
lower (p < 0.01) at D30 as compared to those at D15.
Serum cholesterol, triglyceride, and VLDL levels were
lower (p < 0.01) at D30 as compared to those at D15 inTable 3 Serum glucose level and lipid profile at post treatment day
Control (n = 6) STZ (n = 6)
Glucose level (mg/dl)
At day 15 53.72 ± 3.58 294.11 ± 14.85**
At day 30 54.11 ± 4.89 309.65 ± 33.54**
Lipid profile
Post treatment day 15
Cholesterol (mg/dl) 43.37 ± 3.76 98.24 ± 12.83**
Triglyceride (mg/dl) 72.74 ± 6.15 171.96 ± 39.49
HDL (mg/dl) 10.03 ± 0.83 22.10 ± 2.11**
LDL (mg/dl) 17.31 ± 1.44 38.12 ± 3.65**
VLDL (mg/dl) 14.54 ± 1.23 34.39 ± 7.89
Post treatment day 30
Cholesterol (mg/dl) 44.44 ± 2.04 68.22 ± 10.04*
Triglyceride (mg/dl) 66.29 ± 5.96 201.33 ± 31.23**
HDL (mg/dl) 10.71 ± 0.70 9.95 ± 1.10
LDL (mg/dl) 18.48 ± 1.21 17.16 ± 1.90
VLDL (mg/dl) 13.25 ± 1.19 40.26 ± 6.24**
Data are presented as mean ± SE
HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, VL
*p < 0.05, **p < 0.01 for comparison between the control and STZ group and #p < 0.the metformin group. In the flax and fish oil group,
cholesterol, triglyceride, HDL, LDL, and VLDL levels
were lower (p < 0.01) at D30 as compared to those at
D15 (Table 5).
Expression of genes involved in lipid metabolism
The PPARγ gene expression was lower in the STZ group
(p < 0.05) as compared to that in the control. The treat-
ment with metformin (p < 0.05) and fish oil (p < 0.01)s 15 and 30
Metformin (n = 6) Flax oil (n = 6) Fish oil (n = 6)
340.98 ± 30.14 280.12 ± 12.62 315.36 ± 10.66
300.64 ± 6.75 315.18 ± 16.20 269.23 ± 16.96
58.79 ± 4.47# 87.31 ± 9.03 69.44 ± 3.16
145.58 ± 20.68 114.01 ± 15.45 133.95 ± 23.67
8.09 ± 1.55## 22.93 ± 1.95 13.80 ± 1.17#
13.96 ± 2.68## 39.56 ± 3.37 23.82 ± 2.20#
29.19 ± 4.13 22.80 ± 3.09 26.79 ± 4.73
34.35 ± 4.71## 49.25 ± 2.82 34.62 ± 4.75##
43.14 ± 8.12## 44.81 ± 11.19## 42.03 ± 9.13##
7.97 ± 1.02 13.05 ± 1.06 8.73 ± 0.71
13.75 ± 1.77 22.52 ± 1.83 15.05 ± 1.23
8.62 ± 1.62## 8.96 ± 2.23## 8.40 ± 1.82##
DL very low-density lipoprotein cholesterol
05, ##p < 0.01 for comparison between the STZ group and treatment groups
Fig. 2 a Expression of genes involved in lipid metabolism and inflammation. Data are presented as mean ± SE. *p < 0.05, **p < 0.01 for comparison
between the control and STZ group and #p < 0.05, ##p < 0.01 for comparison between the STZ group and treatment groups. GAPDH glyceraldehyde-3-
phosphate dehydrogenase, PPARγ peroxisome proliferator-activated receptors γ, SREBP1 sterol regulatory element-binding protein, NFκβ nuclear factor
kappa β, FAS fatty acid synthase, ACSL long chain acyl CoA synthetases, MCAT malonyl-CoA-acyl carrier protein transacylase, TNFα tumor necrosis factor
α. b Diagrammatic representation of the possible mechanism of metformin and flax and fish oil on the lipid metabolism and inflammatory cytokines.
PPARγ peroxisome proliferator-activated receptors γ, SREBP sterol regulatory element-binding protein, NFκβ nuclear factor kappa β, FAS fatty acid
synthase, ACSL long chain acyl CoA synthetases, MCAT malonyl-CoA-acyl carrier protein transacylase, TNFα tumor necrosis factor α, up arrow
up-regulation, down arrow down-regulation
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STZ group (Fig. 2a).
The SREBP1 gene expression was higher in the STZ
group (p < 0.01) as compared to that in the control while
treatment with metformin (p < 0.05) and flax and fish oil
lowered (p < 0.01) the expression as compared to that in
the STZ group (Fig. 2a).
The expression of fatty acid synthase (FAS) was higher
in the STZ group (p < 0.01) as compared to that in the
control whereas the expression was lower in metformin(p < 0.05) and flax and fish oil groups (p < 0.01) when
compared to that in the STZ group (Fig. 2a).
The ACSL gene expression was higher in the STZ group
(p < 0.01) as compared to that in the control. Metformin
and flax and fish oil (p < 0.01) lowered the expression of
ACSL as compared to that in the STZ group (Fig. 2a).
The MCAT gene expression was higher in the STZ
group (p < 0.01) as compared to that in the control.
Metformin and flax and fish oil (p < 0.01) lowered the
expression as compared to that in the STZ group (Fig. 2a).
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The NFkβ gene expression was higher in the STZ group
(p < 0.05) as compared to that in the control. The met-
formin group did not show any significant difference as
compared to the STZ group. Flax and fish oil (p < 0.05)
lowered the expression as compared to that in the STZ
group (Fig. 2a).
The TNFα gene expression did not show a significant
difference although it was higher in the STZ group
than in the control (p = 0.123). Metformin (p = 0.155)
and flax (p=0.404) and fish (p= 0.260) oil groups exhibited
decreased expression of TNFα as compared to the STZ group,
but the decrease was not statistically significant (Fig. 2a).
Liver function test markers
At D15, serum SGPT and ALP levels were higher (p < 0.05)
in the STZ group than in the control, but SGOT and
bilirubin levels were comparable to those in the control
(Table 4).
At D30, serum ALP levels were higher (p < 0.01) in the
STZ group as compared to those in the control. Metformin
and flax and fish oil did not affect liver function test
markers at D15 and D30 (Table 4).Table 4 Liver and renal function test markers at post treatment day
Control (n = 6) STZ (n = 6)
Liver function test markers
Post treatment day 15
SGOT (U/ml) 104.10 ± 3.97 123.46 ± 6.98
SGPT (U/ml) 113.08 ± 5.56 167.50 ± 15.28*
ALP (KA Unit) 28.15 ± 4.06 113.46 ± 33.45*
Bilirubin (mg/dl) 0.08 ± 0.18 0.11 ± 0.02
Post treatment day 30
SGOT (U/ml) 113.71 ± 9.81 124.00 ± 8.45
SGPT (U/ml) 87.50 ± 9.10 134.80 ± 24.83
ALP (KA Unit) 15.78 ± 1.59 75.34 ± 6.49**
Bilirubin (mg/dl) 0.08 ± 0.01 0.11 ± 0.03
Renal function test markers
Post treatment day 15
Creatinine (mg/dl) 1.44 ± 0.27 2.38 ± 0.23
Urea (mg/dl) 38.37 ± 3.37 56.11 ± 3.57**
Albumin (g/dl) 2.19 ± 0.15 1.83 ± 0.23
Total protein (g/dl) 4.00 ± 0.18 3.68 ± 0.29
Post treatment day 30
Creatinine (mg/dl) 1.28 ± 0.15 1.69 ± 0.30
Urea (mg/dl) 40.52 ± 4.50 49.38 ± 3.48
Albumin (g/dl) 2.09 ± 0.14 1.70 ± 0.17
Total protein (g/dl) 3.71 ± 0.09 3.42 ± 0.81
Data are presented as mean ± SE
SGOT serum glutamic oxaloacetic transaminase, SGPT serum glutamic pyruvic transa
*p < 0.05, **p < 0.01 for comparison between the control and STZ groupComparison of liver function test markers between D15
and D30 within the groups
In the control group, serum SGPT and ALP levels were
lower (p < 0.05) at D15 as compared to those at D30.
There was no difference in the liver function test
markers in STZ and metformin groups. In both flax oil
and fish oil groups, ALP levels were lower (p < 0.05) at
D30 as compared to those at D15 (Table 5).
Liver histology
In the STZ-induced diabetic group, we observed some
areas with pathological calcification in the partial triad
focal hemorrhages and destruction of some bile ducts. It
also showed destruction of hepatocytes, loss of hepatic
lobules, and conjunction of the central vein. Surprisingly,
the metformin group displayed destruction of some hepa-
tocytes and congestion of the central vein. The flax and
fish oil group displayed near-normal liver histology with-
out any histological detectable anomalies (Fig. 3a).
Renal function test markers
At D15, serum urea (p < 0.01) levels were higher in the
STZ group as compared to those in the control.s 15 and 30
Metformin (n = 6) Flax oil (n = 6) Fish oil (n = 6)
162.11 ± 20.38 133.84 ± 13.60 116.79 ± 8.20
199.83 ± 20.03 202.16 ± 7.52 220.08 ± 12.47
103.88 ± 15.53 91.22 ± 11.19 98.98 ± 4.34
0.12 ± 0.04 0.09 ± 0.01 0.10 ± 0.01
134.48 ± 9.27 120.38 ± 10.69 136.15 ± 6.41
160.33 ± 32.84 150.00 ± 34.53 198.50 ± 22.43
69.63 ± 9.41 53.80 ± 5.78 58.29 ± 10.88
0.14 ± 0.01 0.06 ± 0.02 0.06 ± 0.02
1.86 ± 0.17 1.49 ± 0.27 1.50 ± 0.28
56.88 ± 4.24 46.95 ± 2.26 46.33 ± 3.12
1.61 ± 0.26 1.88 ± 0.11 2.15 ± 0.19
3.86 ± 0.68 3.80 ± 0.25 4.07 ± 0.20
1.61 ± 0.33 1.33 ± 0.10 1.22 ± 0.34
50.88 ± 2.29 60.57 ± 2.35 51.22 ± 4.80
1.54 ± 0.10 1.68 ± 0.11 1.80 ± 0.20
3.08 ± 0.19 3.31 ± 0.14 3.23 ± 0.12
minase, ALP alkaline phosphatase
Table 5 Comparison of biochemical markers between post treatment days 15 and 30 within the groups
Glucose Lipid profile Liver function test markers Renal function test markers
Cholesterol Triglyceride HDL LDL VLDL SGOT SGPT ALP Bilirubin Creatinine Urea Albumin Total protein
p value
Control 0.951 0.833 0.469 0.550 0.550 0.469 0.395 0.037 0.017 1.000 0.612 0.709 0.638 0.192
STZ 0.662 0.108 0.585 0.001 0.001 0.586 0.961 0.274 0.310 0.966 0.103 0.215 0.673 0.453
Metformin 0.243 0.004 0.001 0.950 0.950 0.001 0.245 0.333 0.088 0.667 0.522 0.242 0.813 0.301
Flax oil 0.118 0.007 0.005 0.001 0.001 0.005 0.454 0.170 0.014 0.425 0.600 0.001 0.272 0.123
Fish oil 0.044 0.000 0.005 0.004 0.004 0.005 0.092 0.425 0.011 0.186 0.547 0.413 0.233 0.004
HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, VLDL very low-density lipoprotein cholesterol, SGOT serum glutamic oxaloacetic
transaminase, SGPT serum glutamic pyruvic transaminase, ALP alkaline phosphatase . The p values in italics indicate significant differences in the biochemical
markers, within the groups, between post treatment days 15 and 30
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significant differences in renal function test markers at
D15 and D30 (Table 4).
Comparison of renal function test markers at D15 and
D30 within the groups
There was no difference in the renal function test
markers in the control, STZ, and metformin groups.
The urea levels were higher (p < 0.01) in the flax oil
group while total protein levels were lower (p < 0.05) in
the fish oil group at D30 as compared to those at D15
(Table 5).
Kidney histology
STZ group displayed blood vesicle conjunction, vacuol-
ation of tubular epithelial cells, conjunction of glomeru-
lar capillary, cloudy change in many tubular cells, and
some degeneration of the glomerulus. The metformin
group displayed vacuolation of some tubular epithelial
cells and conjunction of glomerular capillary. The flax
oil and fish oil groups exhibited near-normal architec-
ture and displayed significant recovery of the damage as
compared to the STZ group (Fig. 3b).
Discussion
The general characteristics of STZ-treated diabetic rats
include low body weights and elevated blood glucose
(Howarth et al. 2005). We observed a significant de-
crease in body weights and sustained hyperglycemia in
nicotinamide-STZ-treated rats indicating successful in-
duction of diabetes. In the present study, both metfor-
min and omega-3 fatty acids could not normalize the
glucose levels at D15 which remained higher till D30 of
treatment. However, fish oil treatment lowered the glu-
cose levels at D30 as compared to those at D15. It has
been reported that metformin alone may not adequately
control hyperglycemia (Salama et al. 2013) and omega-3
fatty acids do not directly affect glucose homeostasis
(Woodman et al. 2002). However, several studies have
reported hypoglycemic- and insulin-sensitizing effects ofmetformin (Maheshwari et al. 2014; Mohammadi et al.
2012; Erejuwa et al. 2011) and omega-3 fatty acids
(Jangale et al. 2013) in the STZ-nicotinamide-induced
diabetic rats. Consistent with our findings, metformin
treatment at a dose 500 mg/kg for 8 weeks was not able
to lower blood glucose in diabetic rats (Alhaider et al.
2011). These differences are probably due to variations
in the duration of treatment or dose of metformin/
omega-3 fatty acids which needs further investigation.
Effect of n-3 PUFA intervention on lipid profile
Several reports have documented significant lipid abnor-
malities, like elevated cholesterol, triglyceride, LDL, and
VLDL in diabetic rats (Nasrolahi et al. 2012). We ob-
served increase in the serum cholesterol, triglyceride,
and VLDL levels in the STZ group indicating adverse ef-
fects of elevated glucose on lipid profile. However, long-
term metformin treatment for 30 days reduced these
levels. The beneficial lipid-lowering effects of metformin
have been reported in diabetic rats (Nasrolahi et al.
2012). We have recently reported that long-term use of
oral hypoglycemic agents significantly reduce triglyceride
levels in diabetic men and LDL and HDL levels in dia-
betic women (Ghadge et al. 2014).
In the present study, flax oil and fish oil intervention
normalized all lipid profile parameters at D30 as com-
pared to those at D15. Several studies have reported
triglyceride-lowering effects of dietary fish oil (Bremer
et al. 2014; Hartweg et al. 2008) which have been pri-
marily attributed to EPA and DHA (Skulas-Ray et al.
2011; Egert et al. 2009). The present study indicated ac-
tivation of PPAR and modulation of SREBP1 in the
animals treated with n-3 PUFA which are known to be
the main mechanisms for a lipid-normalizing action of
omega-3 fatty acids (Devarshi et al. 2013).
Modulation of lipid metabolism genes by n-3 PUFA
intervention
In the present study, STZ induction markedly reduced the
expression of PPAR and increased SREBP1 expression
Fig. 3 a Liver histology of control, STZ-induced diabetic, metformin-treated, and flax/fish oil-treated animals. Hematoxylin and eosin-stained cross
sections of paraffin-embedded liver tissues of rats from the control and experimental groups (×40). Liver from the control group shows normal
architecture. Sections of the liver from the STZ-induced diabetic group show severe destruction of hepatic cells, pathological calcification, hemorrhages,
and mild mononuclear cells in the portal tracts. Liver from the metformin-treated group shows some destructive changes and congestion of
some central vein. The liver histology of animals treated with flax oil and fish oil shows completely normal liver architecture without any anatomically
detectable anomalies. b Kidney histology of healthy, STZ-induced diabetic, metformin-treated, and flax/fish oil-treated animals. Hematoxylin and
eosin-stained cross sections of paraffin-embedded kidney tissues of rats from the control and experimental groups (×40). Kidney from the control
group shows normal kidney architecture. Sections of kidney from the STZ diabetic group showed conjunction of glomerular capillary and blood
vesicle. Some tubular epithelial cells show vacuolation and cloudy changes. Kidney from the metformin-treated group shows vacuolation of some
tubular epithelial cells and conjunction of glomerular capillary. The liver histology of animals treated with flax and fish oil shows no considerable
changes and show normal architecture
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(Fig. 2b). Metformin treatment is known to regulate incre-
tin receptor axis via PPAR-dependent pathway in mice
(Maida et al. 2011) and reduce SREBP expression by regu-
lating AMP-activated protein kinase activity in rats (Zhou
et al. 2001). Metformin has been shown to reduce fat con-
tent by decreasing the expression of SREBP1 and FAS (in-
volved in fatty acid synthesis) in rat kidneys (Wang et al.
2006). A recent study reports reduction in PPAR expres-
sion and increase in SREBP expression in diabetic rats
which was restored by dietary fish and flax oil supplemen-
tation (Devarshi et al. 2013). n-3 PUFA and theirmetabolites act as natural ligands for PPAR, promoting
fatty acid oxidation and suppressing the transcription of
lipogenic genes like FAS (Teran-Garcia et al. 2007).
ACSL, catalyzing the thioesterification of fatty acids, is
a target of PPAR and is implicated in the pathogenesis
of diabetes (Phillips et al. 2010). Recent report suggests
that ACSL plays an important role in triglyceride synthe-
sis (Yan et al. 2015). In the present study, STZ-treated
animals showed significantly higher ACSL expression
with high triglyceride levels. However, metformin and
flax and fish oil interventions lowered the expression
and consequently had significantly lower triglyceride
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pression and triglyceride levels in diabetic rats (For-
cheron et al. 2009). Besides triglyceride synthesis by
ACSL, MCAT, a mitochondrial protein, catalyzes trans-
fer of CoA moiety to free thiol group on the acyl carrier
protein in mitochondria, indicating its role in mitochon-
drial fatty acid synthesis (Zhang et al. 2003). Lower ex-
pression of MCAT along with ACSL has beneficial
effects in normalizing the fatty acid and triglyceride
levels (Li et al. 2009; Zhang et al. 2003). In the present
study also, metformin and flax and fish oil showed re-
duced MCAT expression indicating lower fatty acid syn-
thesis and normal lipid profile (Fig. 2b).
Modulation of inflammatory cytokine genes by n-3 PUFA
intervention
T2DM is a chronic inflammatory disease where transcription
factor NFkβ activates the transcription of inflammatory cyto-
kines like TNFα increasing the risk of secondary complica-
tions owing to their pro-atherogenic nature (Jagannathan-
Bogdan et al. 2011). In the present study, NFkβ expression
was higher in the STZ group which was significantly lowered
by flax and fish oil (Fig. 2b). However, TNFα expression was
not significantly altered in the STZ group and treatment
groups. Hyperglycemia-induced NFkβ activation in ex vivo
isolated PBMCs has been reported in type 1 diabetic patients
(Hofmann et al. 1998). Metformin administration has also
been shown to downregulate the expression of NFkβ and
TNFα and ameliorate β-cell dysfunction (Liu et al. 2014) in
diabetes. Recent review highlights the role of n-3 PUFA in
reducing TNFα expression (Ellulu et al. 2015).
Effect of n-3 PUFA intervention on liver function test
markers
In the present study, SGPT and ALP levels were higher in
the STZ group at D15 while ALP remained higher at D30
as compared to that in the control group. There are re-
ports indicating hepatic dysfunction due to higher levels
of liver enzymes such as SGPT, SGOT, and ALP in STZ-
induced diabetic rats (Sajitha et al. 2012). We have re-
cently reported higher serum SGPT and bilirubin levels in
diabetic male subjects and SGPT levels in diabetic female
subjects (Ghadge et al. 2015). The biochemical alterations
in the hepatic function markers observed in the present
study were also associated with destructive changes in he-
patocytes and accumulation of lipid droplets.
In this study, metformin treatment did not affect other
markers. In contrast, a study in diabetic rats treated with
metformin is reported to have elevated bilirubin levels
(Nasrolahi et al. 2012). Liver section analysis of these an-
imals displayed destruction of some hepatocytes and
congestion of the central vein. A recent study reported
mild granular degeneration, mild swelling (narrow sinus-
oidal capillaries), and normal hepatic architecture in themetformin-treated diabetic rats (Motshakeri et al. 2014).
Some case report studies also demonstrated that metfor-
min induces hepatotoxicity in diabetic subjects raising
concern about its efficacy and safety profile (Miralles-
Linares et al. 2012; Cone et al. 2010).
Hepatoprotective effects of n-3 PUFA in chemically in-
duced hepatotoxicity have been reported earlier from our
laboratory (Chavan et al. 2013). In the present study, flax
and fish oil intervention showed progressive effects in low-
ering ALP levels at D30 as compared to D15. Additionally,
both of these groups exhibited normal hepatic architecture
and displayed significant recovery of destructive changes.
Effect of n-3 PUFA on renal function test markers
Serum urea levels were higher in the STZ group at D15 as
compared to those in the control group. Although renal
function test markers at D30 were comparable to those of
the control group, STZ induction still affected kidney hist-
ology and are consistent with other reports (Ahmed et al.
2014; Zafar et al. 2009). The metformin group showed no
significant changes in the renal function test markers
against the STZ group. However, we observed vacuolation
of tubular epithelial cells in some tubules and conjunction
of glomerular capillary in metformin-treated group. Simi-
lar findings like moderate cellular hydropic degeneration,
atrophied renal corpuscle, and mild congestion of glom-
erular capillaries were reported in metformin-treated dia-
betic rats (Motshakeri et al. 2014). Further, in the present
study, fish oil treatment progressively lowered total protein
levels at D30 as compared to those at D15. Flax and fish
oil also showed normal kidney histology. Similarly, dietary
flax and fish oil have shown to improve renal abnormal-
ities in rats (Hassan et al. 2015; Velasquez et al. 2003).
Conclusion
In conclusion, the treatment with metformin and flax/fish
oil intervention in diabetic rats improves serum lipid profile
and the expression of transcription factors modulating lipid
metabolism such as PPAR-γ and SREBP1 and lowers
atherogenic cytokine like NFkβ. In the present study, flax
oil and/or fish oil exhibited hepatoprotective and nephro-
protective effects under uncontrolled hyperglycemic states.
The combination therapy of metformin and n-3 PUFA
intervention is worth investigating in T2DM subjects.
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